Biomx Inc (PHGE) - Total Liabilities
Based on the latest financial reports, Biomx Inc (PHGE) has total liabilities worth $15.68 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Biomx Inc annual equity growth to track the company's year-over-year net asset growth rate.
Biomx Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Biomx Inc's total liabilities have evolved over time, based on quarterly financial data.
Biomx Inc Competitors by Total Liabilities
The table below lists competitors of Biomx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brave Bison Group PLC
LSE:BBSN
|
UK | GBX38.40 Million |
|
American Rebel Holdings Inc
NASDAQ:AREB
|
USA | $23.54 Million |
|
Avidian Gold Corp
V:AVG
|
Canada | CA$102.36K |
|
Consolidated Firstfund Capital Corp
V:FFP
|
Canada | CA$167.48K |
|
MFC Industrial Real Estate Investment Trust
BK:MIT
|
Thailand | ฿139.44 Million |
|
Baroyeca Gold & Silver Inc
V:BGS
|
Canada | CA$304.13K |
|
DCM Financial Services Limited
NSE:DCMFINSERV
|
India | Rs713.56 Million |
|
Accesso Technology Group PLC
LSE:ACSO
|
UK | GBX59.54 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Biomx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biomx Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomx Inc (2017–2024)
The table below shows the annual total liabilities of Biomx Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.09 Million | -13.04% |
| 2023-12-31 | $21.95 Million | -10.39% |
| 2022-12-31 | $24.49 Million | -19.58% |
| 2021-12-31 | $30.45 Million | +136.20% |
| 2020-12-31 | $12.89 Million | +68.22% |
| 2019-12-31 | $7.67 Million | +203.20% |
| 2018-12-31 | $2.53 Million | +2.76% |
| 2017-12-31 | $2.46 Million | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more